- Corporate Cost-Cutting: Will Early Gains Turn to Pain?
- Earnings Woke Up the Market, but Can It Continue?
- China Regulator: Bank Lending May Be Overheating
- Fortress Names Ex-Fannie Head Mudd as CEO
- The 15 Most Expensive Cities on Earth
- Box Office: 'Potter' Hauls in $160 Million in 5 Days
- Healthcare Debate: Obama Tries to Regain Upper Hand
- Berkshire Hathaway Rallies for Best Week Since March
- Cramer: Know When to Go Long—I Haven't Always
- Berkshire Hathaway Rallies 6% For Best Week Since March Lows
- Market 360: The Week's Best & Worst
- How Bad is the DVD Decline and Who Suffers?
- Teva, Propofol And Michael Jackson
- Pros Say: US Market Rally Likely to Continue
- Gold Miner Attracting Big Bull Interest
- Dick Bove: Next Week’s Bank Earnings Will Be ‘Terrible’
- Jesuthasan: 'Deleveraging Pay-The Proof is in the Bathwater'
- Art Cashin: Traders Don't Trust 'Short Term' Earnings
- Interior to halt uranium mining at Grand Canyon
- AOL tries to recapture that startup feeling
- Opposition Republicans attack Obama on health care
- Retail stocks see new calculus on investors' hopes
- J.C. Penney takes on Manhattan
- GRD board supports $86 million takeover by AMEC
- Report: Suspect killed during Brazil zoo robbery
- Chairman of business journals dies of bee sting
- Japanese stock markets closed for national holiday
Covidien gets Canadian OK for generic Cardiolite
Text Size 
ST. LOUIS - Medical device maker and health care company Covidien PLC said Monday it recieved Canadian regulatory approval for a generic version of the heart disease imaging agent Cardiolite.
Cardiolite, which is made by Bristol-Myers Squibb, is used as a diagnostic tool in cardiac stress tests.
Covidien said it expects its generic version of the product to be available in Canada this summer. It also sells generic versions in the U.S., Denmark, the U.K., Germany, and Puerto Rico.
Shares of Ireland-based Covidien fell 69 cents to $35.51 in morning trading.
Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Print
Email
Data is a real-time snapshot *Data is delayed at least 15 minutes